2,589 results match your criteria treated sorafenib

The impact of portal vein tumor thrombosis on survival in patients with hepatocellular carcinoma treated with different therapies: A cohort study.

PLoS One 2021 7;16(5):e0249426. Epub 2021 May 7.

Department of Internal Medicine I, University Medical Center Mainz, Mainz, Germany.

Background: Portal vein tumor thrombosis (PVTT) is a frequent complication of hepatocellular carcinoma (HCC), which leads to classification as advanced stage disease (regardless of the degree of PVTT) according to the Barcelona Clinic Liver Cancer Classification. For such patients, systemic therapy is the standard of care. However, in clinical reality, many patients with PVTT undergo different treatments, such as resection, transarterial chemoembolization (TACE), selective internal radiation therapy (SIRT), or best supportive care (BSC). Read More

View Article and Full-Text PDF

Lenvatinib-induced multiorgan adverse events in Hurthle cell thyroid cancer: A case report.

World J Clin Oncol 2021 Apr;12(4):272-281

Department of Medicine, King Faisal Specialist Hospital, Research Centre, Al Faisal University, Riyadh 12713, Saudi Arabia.

Background: The management of metastatic progressive radioiodine-resistant differentiated thyroid cancer remains challenging for clinicians. The availability of tyrosine kinase inhibitors (TKIs), sorafenib and lenvatinib, within the last decade has expanded treatment options; however, these lead to significant adverse effects, which may curtail their use.

Case Summary: We report the case of a 47-year-old female with Hurthle cell thyroid cancer who underwent total thyroidectomy followed by radioiodine ablation. Read More

View Article and Full-Text PDF

Erythema multiforme after treatment with sorafenib.

Proc (Bayl Univ Med Cent) 2021 Mar 8;34(3):380-381. Epub 2021 Mar 8.

Department of Dermatology, Baylor Scott & White Medical Center - Temple, Temple, Texas.

Sorafenib, an oral chemotherapeutic agent used in the treatment of solid tumors, is associated with a variety of adverse cutaneous drug reactions in up to 90% of patients. Infrequently, delayed-type hypersensitivity reactions such as erythema multiforme occur. This case describes a child treated with sorafenib for a retrosternal desmoid tumor who developed widespread erythema multiforme across his extremities, trunk, face, and mucosal membranes. Read More

View Article and Full-Text PDF

Pristimerin synergistically sensitizes conditionally reprogrammed patient derived-primary hepatocellular carcinoma cells to sorafenib through endoplasmic reticulum stress and ROS generation by modulating Akt/FoxO1/p27 signaling pathway.

Phytomedicine 2021 Apr 4;86:153563. Epub 2021 Apr 4.

Department of Pharmacy, The First Affiliated Hospital, Sun Yat-sen University, 510080 Guangzhou, China. Electronic address:

Background: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-associated mortality worldwide. Sorafenib (SORA), as a first-line therapeutic drug, has been used to treat HCC, but resistance poses a major limitation on the efficacy of SORA chemotherapy. Pristimerin (PRIS), a natural bioactive component isolated from various plant species in the Celastraceae and Hippocrateaceae families, has been reported to exhibit outstanding antitumor effects in several types of cells in vitro. Read More

View Article and Full-Text PDF

Radiologic Response Combined with Dermatologic Toxicities is the Most Robust Predictor of Survival Benefits in Patients with Inoperable Hepatocellular Carcinoma After Transarterial Chemoembolization Plus Sorafenib Therapy.

Cardiovasc Intervent Radiol 2021 May 4. Epub 2021 May 4.

Department of Radiology, The Seventh Affiliated Hospital, Sun Yat-Sen University, 628 Zhenyuan Road, Shenzhen, P.R. China.

Purpose: The survival benefits of patients with inoperable hepatocellular carcinoma (HCC) who undergo transarterial chemoembolization (TACE) and receive sorafenib therapy remain controversial. We aimed to identify clinical predictors in patients with inoperable HCC undergoing TACE and receiving sorafenib.

Methods: Between January 2014 and December 2017, 148 consecutive patients with inoperable HCC who were treated with TACE plus sorafenib were retrospectively analyzed. Read More

View Article and Full-Text PDF

Lenvatinib in severe hypoglycemia associated with hepatocelular carcinoma.

Rev Esp Enferm Dig 2021 May 5. Epub 2021 May 5.

UGC Aparato Digestivo, Hospital de Poniente, España.

We present the case of a 24-year-old man with multicentric hepatocellular carcinoma over HBV cirrhosis treated with Sorafenib and Tenofovir. He comes to our center for repeated episodes of symptomatic hypoglycemia that cannot be managed with standard measures. After ruling out different possibilities, the suspicion of hypoglycemia due to a non-islet cell tumor was finally confirmed. Read More

View Article and Full-Text PDF

Hemistepsin a Induces Apoptosis of Hepatocellular Carcinoma Cells by Downregulating STAT3.

Int J Mol Sci 2021 Apr 29;22(9). Epub 2021 Apr 29.

College of Korean Medicine, Daegu Haany University, Gyeongsan 38610, Korea.

(Bunge) Bunge is a biennial medicinal plant possessing beneficial effects including anti-inflammation, and hemistepsin A (HsA) isolated from has been known as a hepatoprotective sesquiterpene lactone. In this report, we explored the cytotoxic effects of on hepatocellular carcinoma (HCC) cells and investigated the associated bioactive compounds and their relevant mechanisms. From the viability results of HCC cells treated with various extracts, HsA was identified as the major compound contributing to the -mediated cytotoxicity. Read More

View Article and Full-Text PDF

High Trough Levels of Everolimus Combined to Sorafenib Improve Patients Survival After Hepatocellular Carcinoma Recurrence in Liver Transplant Recipients.

Transpl Int 2021 May 1. Epub 2021 May 1.

AP-HP Hôpital Paul Brousse, Centre Hépato-Biliaire ; Inserm, UMR-S 1193, Université Paris- Saclay, 94805, Villejuif, France.

Recurrence of hepatocellular carcinoma (HCC) following liver transplantation (LT) occurs in 10%-20% of patients transplanted for HCC. The treatment of HCC recurrence after LT remains a challenge. Consecutive patients who underwent LT for HCC between 2005 and 2015 at our center were recruited. Read More

View Article and Full-Text PDF

Combination of Sorafenib and Transarterial Chemoembolization in Selected Patients with Advanced-Stage Hepatocellular Carcinoma: A Retrospective Cohort Study at Three German Liver Centers.

Cancers (Basel) 2021 Apr 28;13(9). Epub 2021 Apr 28.

Department of Medicine 1, University Hospital Frankfurt, Goethe-University, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany.

Background And Aims: Systemic treatment with sorafenib has been the standard of care (SOC) in patients with advanced Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma (HCC) for more than a decade. TACE has been reported to allow better local tumor control in selected patients with BCLC stage C HCC.

Methods: A retrospective analysis of patients with BCLC stage C HCC that were treated with sorafenib and TACE was conducted; they were compared to BCLC stage C patients treated either with TACE or sorafenib in the same period of time outside a clinical trial. Read More

View Article and Full-Text PDF

Selective Anti-Cancer Effects of Plasma-Activated Medium and Its High Efficacy with Cisplatin on Hepatocellular Carcinoma with Cancer Stem Cell Characteristics.

Int J Mol Sci 2021 Apr 12;22(8). Epub 2021 Apr 12.

Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul 03722, Korea.

Hepatocellular carcinoma (HCC) is a major histological subtype of primary liver cancer. Ample evidence suggests that the pathological properties of HCC originate from hepatic cancer stem cells (CSCs), which are responsible for carcinogenesis, recurrence, and drug resistance. Cold atmospheric-pressure plasma (CAP) and plasma-activated medium (PAM) induce apoptosis in cancer cells and represent novel and powerful anti-cancer agents. Read More

View Article and Full-Text PDF

Targeted therapy in Xp11 translocation renal cell carcinoma.

Klin Onkol 2021 ;34(2):137-140

Background: Translocation renal cell carcinoma (TRCC) is a rare form of RCC affecting mostly children and young adults with the occurrence of only 1-5% of all renal cell carcinomas. These carcinomas are associated with different translocations on a short arm of chromosome X in the region 11.2, which results in genetic modification of the p arm containing the transcription factor E3 gene. Read More

View Article and Full-Text PDF
January 2021

The Impact of Sorafenib in Combination with Transarterial Chemoembolization on the Outcomes of Intermediate-Stage Hepatocellular Carcinoma.

Asian Pac J Cancer Prev 2021 Apr 1;22(4):1217-1224. Epub 2021 Apr 1.

Department of Surgery, Kansai Medical University, Hirakata, Osaka, Japan.

Background: We investigated the treatment outcomes and hepatic reserve of transarterial chemoembolization (TACE)-refractory patients with recurrent advanced hepatocellular carcinoma (HCC) treated with TACE plus sorafenib.

Methods: Forty-one patients with intermediate-stage HCC defined as being TACE refractory on imaging were treated with sorafenib and TACE between 2009 and 2012 and comprised the combination treatment group. Twenty-nine patients who received repeated TACE after becoming refractory to TACE between 2005 and 2008 comprised the TACE continuation group. Read More

View Article and Full-Text PDF

Therapeutic Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma Recurrence After Liver Transplantation: A Systematic Review and Meta-Analysis.

Turk J Gastroenterol 2021 Jan;32(1):30-41

Department of Hepatobiliary Surgery, Peking University People's Hospital, Beijing, China;Peking University Institute for Organ Transplantation, Beijing, China;Beijing Key Laboratory of Liver Cirrhosis and Liver Cancer, Beijing, China.

Background: Hepatocellular carcinoma (HCC) recurrence is still threatening patient survival after liver transplantation (LT). The efficacy and safety of sorafenib in the setting of post-LT recurrence are still equivocal. This study aims to disclose the efficacy and safety profile of sorafenib in treating post-LT HCC recurrence. Read More

View Article and Full-Text PDF
January 2021

Insulin-like growth factor 1/Child-Turcotte-Pugh composite score as a predictor of treatment outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib.

Oncotarget 2021 Apr 13;12(8):756-766. Epub 2021 Apr 13.

Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Background: Sorafenib was the first systemic therapy approved for the treatment of Child-Turcotte-Pugh (CTP) class A patients with advanced hepatocellular carcinoma (HCC). However, there are no biomarkers to predict survival and treatment outcomes and guide HCC systemic therapy. Type 1 insulin-like growth factor (IGF-1)/CTP composite score has emerged as a potential hepatic reserve assessment tool. Read More

View Article and Full-Text PDF

Post-transplantation maintenance with sorafenib or midostaurin for FLT3 positive AML patients - a multicenter retrospective observational study.

Leuk Lymphoma 2021 Apr 21:1-7. Epub 2021 Apr 21.

Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah-Tikva, Israel.

The role of post allogeneic stem-cell transplantation (AlloSCT) FLT3 inhibition for acute myeloid leukemia in the real-world setting is unclear, especially in the era of widespread pre-transplant use of tyrosine kinase inhibitors (TKIs). In a multicenter nationwide study, we assessed 41 patients who were treated with post-transplant TKIs (sorafenib,  = 23, midostaurin,  = 18). The majority also received TKIs pre-transplant ( = 32, 79%). Read More

View Article and Full-Text PDF

Sorafenib combined with dasatinib therapy inhibits cell viability, migration, and angiogenesis synergistically in hepatocellular carcinoma.

Cancer Chemother Pharmacol 2021 Apr 16. Epub 2021 Apr 16.

Department of Pathology, Chang Bing Show-Chwan Memorial Hospital, 6, Lugong Road, Lukang Zhen, Changhua County, 505, Taiwan.

Purpose: Sorafenib is a multikinase inhibitor used for treatment of advanced hepatocellular carcinoma. Sorafenib resistance may be related to Src-induced cell migration and angiogenesis, which are regulated by cancer stem cell activation and release of vascular endothelial growth factor. Dasatinib is a Src inhibitor that inhibits Src phosphorylation and suppresses Src-associated cell migration and angiogenesis. Read More

View Article and Full-Text PDF

Risk adapted therapeutic strategy in newly diagnosed acute myeloid leukemia: Refining the outcomes of ELN 2017 intermediate-risk patients.

Leuk Res 2021 Mar 29;105:106568. Epub 2021 Mar 29.

Hematology-Oncology Division, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon. Electronic address:

Introduction: Despite advances in the treatment of acute myeloid leukemia (AML), cytotoxic chemotherapy remains the standard induction regimen.

Patients And Methods: In this single center retrospective study, we assessed outcomes of 99 consecutive adult AML patients treated with a risk-adapted strategy with a median follow-up of 35.5 months. Read More

View Article and Full-Text PDF

Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial.

J Cancer Res Clin Oncol 2021 Apr 14. Epub 2021 Apr 14.

Department of Radiology, University Hospital, Ludwig Maximilian University of Munich, Marchioninistrasse 15, 81377, Munich, Germany.

Purpose: To explore the potential correlation between baseline interleukin (IL) values and overall survival or objective response in patients with hepatocellular carcinoma (HCC) receiving sorafenib.

Methods: A subset of patients with HCC undergoing sorafenib monotherapy within a prospective multicenter phase II trial (SORAMIC, sorafenib treatment alone vs. combined with Y90 radioembolization) underwent baseline IL-6 and IL-8 assessment before treatment initiation. Read More

View Article and Full-Text PDF

SPARC regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma.

Cancer Biomark 2021 Apr 2. Epub 2021 Apr 2.

Oncology Department, Shanghai International Medical Center, Shanghai, China.

Background: Secreted protein acidic and rich in cysteine (SPARC) is implicated in cancer progression, but its role and associated molecular mechanism in the sorafenib sensitivity of hepatocellular carcinoma cells (HCC) remains elusive.

Methods: Human HCC cell lines Hep3B and HepG2 were treated with sorafenib alone or combined with activator or inhibitor of ferroptosis. Cell viability assay, reactive oxygen species (ROS) assay, lactate dehydrogenase (LDH) assay and western blot were used to study the regulatory mechanism of SPARC on HCC cells. Read More

View Article and Full-Text PDF

Therapeutic efficacy of lenvatinib as third-line treatment after regorafenib for unresectable hepatocellular carcinoma progression.

Hepatol Res 2021 Apr 10. Epub 2021 Apr 10.

Department of Gastroenterology, Okayama City Hospital, Okayama, Japan.

Aim: Multiple molecular agents have been developed for treating unresectable hepatocellular carcinoma. This study aimed to elucidate the clinical efficacy of sequential treatment with lenvatinib after regorafenib failure.

Methods: From June 2017 to October 2020, 63 patients with Child-Pugh A and treated with regorafenib followed by sorafenib were enrolled (median age 71 years, 52 men, Barcelona Clinic Liver Cancer B:C = 23:40). Read More

View Article and Full-Text PDF

Recurrent hepatogastric fistula during lenvatinib therapy for advanced hepatocellular carcinoma managed by over-the-scope clip closure: a case report.

J Rural Med 2021 Apr 1;16(2):102-110. Epub 2021 Apr 1.

Department of Gastroenterology/Internal Medicine, Gifu University Graduate School of Medicine, Japan.

Lenvatinib is an oral multitarget tyrosine kinase inhibitor (mTKI) and is recommended for patients with advanced hepatocellular carcinoma (HCC) with Child-Pugh A liver function, who are not amenable to surgical resection, locoregional treatment, or transcatheter arterial chemoembolization. Hepatogastric fistula is a rare complication with a poor prognosis in patients with HCC. Previous reports on fistula formation during mTKI therapy for HCC were all associated with sorafenib. Read More

View Article and Full-Text PDF

Comparing Real World, Personalized, Multidisciplinary Tumor Board Recommendations with BCLC Algorithm: 321-Patient Analysis.

Cardiovasc Intervent Radiol 2021 Apr 6. Epub 2021 Apr 6.

Section of Interventional Radiology, Department of Radiology, Robert H. Lurie Comprehensive Cancer Center, Northwestern Memorial Hospital, Northwestern University, 676 N. St. Clair, Suite 800, Chicago, IL, 60611, USA.

Purpose: To evaluate hepatocellular carcinoma (HCC) treatment allocation, deviation from BCLC first-treatment recommendation, and outcomes following multidisciplinary, individualized approach.

Methods: Treatment-naïve HCC discussed at multidisciplinary tumor board (MDT) between 2010 and 2013 were included to allow minimum 5 years of follow-up. MDT first-treatment recommendation (resection, transplant, ablation, transarterial radioembolization (Y90), transarterial chemoembolization, sorafenib, palliation) was documented, as were subsequent treatments. Read More

View Article and Full-Text PDF

The Role of Cabozantinib as a Therapeutic Option for Hepatocellular Carcinoma: Current Landscape and Future Challenges.

J Hepatocell Carcinoma 2021 29;8:177-191. Epub 2021 Mar 29.

Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (Milan), 20090, Italy.

The systemic treatment of advanced hepatocellular carcinoma (HCC) has significantly changed over the last years, with the introduction of two new standard-of-care first-line treatments (lenvatinib and the combination of atezolizumab and bevacizumab) and the success of several new agents in second line. In particular, after the approval of regorafenib, ramucirumab and cabozantinib, the landscape of second-line treatment has become notably complex, providing a serious challenge in clinical practice. In this review, we focus on cabozantinib, a multikinase inhibitor which was proven effective in improving overall and progression-free survival of patients previously treated with sorafenib in the randomized Phase III CELESTIAL trial. Read More

View Article and Full-Text PDF

Immune-Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Synopsis of Response Rates.

Oncologist 2021 Apr 5. Epub 2021 Apr 5.

Blacktown Clinical School, Western Sydney University, Sydney, New South Wales, Australia.

Hepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related death worldwide. A first-line standard of care, sorafenib results in median overall survival of 12 months in patients with Child-Pugh class A disease and 6 months in patients with Child-Pugh class B disease with objective response rates (ORRs) not exceeding 19%. These low efficacy rates have driven research on alternative therapeutic options, particularly immune-checkpoint inhibitors (ICIs). Read More

View Article and Full-Text PDF

Efficacy of Ramucirumab Sorafenib as Subsequent Treatment for Hepatocellular Carcinoma.

Anticancer Res 2021 Apr;41(4):2187-2192

Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan;

Background/aim: The present study aimed to examine the therapeutic efficacy of ramucirumab compared with that of sorafenib as subsequent systemic therapy for patients with hepatocellular carcinoma (HCC) and serum α-fetoprotein (AFP) levels ≥400 ng/ml.

Patients And Methods: In our prospectively registered, real-world cohort, 13 and 11 patients treated with ramucirumab or sorafenib, respectively, were analyzed. Progression-free survival (PFS) was primarily compared between the ramucirumab and sorafenib groups. Read More

View Article and Full-Text PDF

Thyroid Cancers: From Surgery to Current and Future Systemic Therapies through Their Molecular Identities.

Int J Mol Sci 2021 Mar 18;22(6). Epub 2021 Mar 18.

Endocrine Unit, Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy.

Differentiated thyroid cancers (DTC) are commonly and successfully treated with total thyroidectomy plus/minus radioiodine therapy (RAI). Medullary thyroid cancer (MTC) is only treated with surgery but only intrathyroidal tumors are cured. The worst prognosis is for anaplastic (ATC) and poorly differentiated thyroid cancer (PDTC). Read More

View Article and Full-Text PDF

Frequency of pre-treatment may not increase the immune-related adverse events of RCC patients treated with nivolumab.

Medicine (Baltimore) 2021 Apr;100(13):e25402

Department of Urology, Gifu University Graduate School of Medicine, Gifu.

Abstract: Nivolumab has shown good prognosis in renal cell carcinoma (RCC) patients previously treated with targeted therapy. We aimed to study irAE (immune-related adverse event) due to nivolumab and numbers of previous treatment lines in RCC patients. Between October 2016 and November 2019, 114 patients were treated with nivolumab as second- and later-line therapy. Read More

View Article and Full-Text PDF

In pursuit of a selective hepatocellular carcinoma therapeutic agent: Novel thalidomide derivatives with antiproliferative, antimigratory and STAT3 inhibitory properties.

Eur J Med Chem 2021 May 10;217:113353. Epub 2021 Mar 10.

School of Molecular Sciences, The University of Western Australia, Crawley, WA, 6009, Australia. Electronic address:

Advanced stage liver cancer is predominantly treated with the multi-kinase inhibitor sorafenib; however, this therapeutic agent lacks selectivity in its cytotoxic actions and is associated with poor survival outcomes. Herein we report the design and preparation of several thalidomide derivatives, including a variety of novel thioether-containing forms that are especially rare in the literature. Importantly, two of the derivatives described are potent antiproliferative agents with dose-dependent selectivity for tumorigenic liver progenitor cells (LPC) growth inhibition (up to 36% increase in doubling time at 10 μM) over non-tumorigenic cells (no effect at 10 μM). Read More

View Article and Full-Text PDF

Efficacy of adavosertib therapy against anaplastic thyroid cancer.

Endocr Relat Cancer 2021 Apr 29;28(5):311-324. Epub 2021 Apr 29.

Department of Internal Medicine, New Taipei Municipal TuCheng Hospital, New Taipei City, Taiwan.

Wee1 is a kinase that regulates the G2/M progression by the inhibition of CDK1, which is critical for ensuring DNA damage repair before initiation of mitotic entry. Targeting Wee1 may be a potential strategy in the treatment of anaplastic thyroid cancer, a rare but lethal disease. The therapeutic effects of adavosertib, a Wee1 inhibitor for anaplastic thyroid cancer was evaluated in this study. Read More

View Article and Full-Text PDF